Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when FENC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsFennec Pharmaceuticals grants 50,000 stock options to three new employees
Filed May 18, 2026 · Period ending May 18, 2026 · ~1 min read
Key Changes
-
low
Fennec granted stock options for 50,000 shares to three new employees under its 2026 Equity Inducement Plan, with an exercise price of $9.75 per share and a ten-year term.
Item 5.02 verify on EDGAR → -
low
Options vest over three years: one-third after the first year, then monthly over the following 24 months, contingent on continued employment.
Item 5.02 verify on EDGAR → -
low
Grants were made as inducement awards under Nasdaq Listing Rule 5635(c)(4), allowing equity grants outside shareholder-approved plans to attract new hires.
Item 5.02 verify on EDGAR →
Summary
Fennec Pharmaceuticals disclosed routine equity compensation for new employees, granting stock options for 50,000 shares at $9.75 per share. The grants were made under the company's 2026 Equity Inducement Plan and comply with Nasdaq rules that permit companies to offer equity outside of shareholder-approved plans specifically to attract new talent.
The options have a standard three-year vesting schedule designed to retain employees. For retail investors, this is a procedural disclosure with minimal impact. The 50,000 shares represent a small portion of equity and are typical for new-hire compensation packages. The filing signals that Fennec is adding staff, which could indicate operational expansion, but provides no details on the roles or strategic rationale. Watch for future disclosures about headcount growth or business development that might explain why the company is hiring.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
On May 11, 2026, the Compensation Committee of the Board of Directors of Fennec Pharmaceuticals Inc. approved grants of stock options to purchase an aggregate of 50,000 common shares to three new employees under the Company’s 2026 Equity Inducement Plan, with a grant date of May 18, 2026, as inducement awards pursuant to Nasdaq Listing Rule 5635(c) (4).
The company granted stock options for 50,000 shares to three new employees as inducement awards under the 2026 Equity Inducement Plan. These grants comply with Nasdaq rules for inducement equity awards, which allow companies to grant equity outside of shareholder-approved plans to attract new hires.
Added in current filing · verify on EDGAR →
The options have an exercise price of $9.75 per share, a ten-year term and vest over three years, with one-third vesting on the first anniversary of the grant date and the balance vesting monthly over the following 24 months, subject to continued employment.
The options have a $9.75 exercise price and ten-year term, with a three-year vesting schedule: one-third vests after one year, then the remaining two-thirds vest monthly over the next 24 months. This is a standard vesting structure designed to retain new employees.
Event · Item 8.01 — Other Events
Procedural 8-K filing referencing Item 8.01 and Exhibit 99.1 with standard non-filing language; no material business event disclosed.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Item 8.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
The 8-K references Item 8.01 and an attached Exhibit 99.1 with standard boilerplate language indicating the disclosure is not deemed filed for liability purposes under securities laws. No substantive business event, financial result, or corporate action is described in the provided text.
Event · Item 9.01 — Financial Statements and Exhibits
Fennec Pharmaceuticals filed an 8-K attaching a press release dated May 18, 2026; no material event details disclosed in the filing body.
Added in current filing · view on EDGAR →
Exhibit 99.1 Press Release dated May 18, 2026
The 8-K references an attached press release dated May 18, 2026, but the filing body does not disclose the content or subject matter of that release. Without the exhibit text, the nature and materiality of the disclosed event cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 26, 2026 · How we verify